Naringenin alters the pharmacokinetics of ranolazine in part through the inhibition of cytochrome P450 (3A4) and P-glycoprotein
Abstract Background This study set out to look at how naringenin affected the pharmacokinetics of ranolazine in rats. The pharmacokinetic investigation of ranolazine in rats following oral administration of ranolazine with or without coadministration of naringenin was successfully conducted using th...
Saved in:
Main Author: | Faisal Alotaibi (Author) |
---|---|
Format: | Book |
Published: |
SpringerOpen,
2023-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of genetic polymorphisms on the interplay of P-glycoprotein transporter and cytochrome P450 enzymes: Pharmacokinetics of risperidone
by: Yong-Bok Lee
Published: (2016) -
Effects of resveratrol on P-glycoprotein and cytochrome P450 3A in vitro and on pharmacokinetics of oral saquinavir in rats
by: Li JP, et al.
Published: (2016) -
Physiologically‐Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P‐glycoprotein and Cytochrome P450 3A
by: Yukio Otsuka, et al.
Published: (2020) -
Succinic acid inhibits the activity of cytochrome P450 (CYP450) enzymes
by: Hao Wang, et al.
Published: (2020) -
Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P‐glycoprotein-cytochrome P450 3A4 dual substrates
by: Xian Pan, et al.
Published: (2021)